As cancer itself is known to be a driver of inflammation and activation of hemostasis [[27], [28], [29]], we evaluated the difference in CRP levels and hemostatic biomarkers in the subgroup of patients with tumor types considered to have a low thrombotic risk (breast and prostate cancer) [26]. This evidence concerns the gene CRP and prostate cancer.